MLICM
OMGA

Metropolitan Life Insurance Company (MetLife)’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,423
Closed -$7.97K – 2459
2023
Q2 		$7.97K Buy
+1,423
New +$11.1K ﹤0.01% 2398

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OMGA Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q3 2023, closing a stake of 1,423 shares — an estimated $7.97K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OMGA in Q2 2023 and held it in 1 quarter. The position peaked at $7.97K in Q2 2023. 58 funds tracked by Wall St. Rank hold OMGA as of Q3 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,423 Omega Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $7.97K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Omega Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Omega Therapeutics, Inc. Common Stock position peaked at $7.97K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.